New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
19:14 EDTGILDGilead coverage resumed with an Outperform at RW Baird
Target $86.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
August 18, 2014
16:00 EDTGILDOptions Update; August 18, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
August 15, 2014
16:00 EDTGILDOptions Update; August 15, 2014
iPath S&P 500 VIX Short-Term Futures up 1c to 28.88. Option volume leaders: AAPL GILD NFLX PBR TWTR TSLA MNKD AMZN C according to Track Data.
10:01 EDTGILDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTGILDGilead initiated with an Outperform at FBR Capital
Subscribe for More Information
06:12 EDTGILDGilead announced favorable ruling in arbitration against Roche
Gilead (GILD) announced that an arbitration panel determined that Roche (RHHBY) failed to establish any of their claims and ruled in favor of Gilead. As a result, Roche is not entitled to any damages or other relief. In March 2013, Roche initiated an arbitration against Gilead and Pharmasset, predecessor to Gilead Pharmasset, regarding a 2004 collaboration agreement between Roche and Pharmasset. In the arbitration demand, Roche asserted that it had an exclusive license to sofosbuvir pursuant to the collaboration agreement because sofosbuvir, a prodrug of a uridine monophosphate analog, is allegedly a prodrug of PSI-6130, a cytidine analog. Roche further claimed that, because it had exclusive rights to sofosbuvir, it also had an exclusive license to a patent covering sofosbuvir, and that we infringed that patent by selling and offering for sale products containing sofosbuvir.
August 14, 2014
16:01 EDTGILDOptions Update; August 14, 2014
Subscribe for More Information
August 13, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
August 11, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:29 EDTGILDGilead price target raised to $110 from $90 at Argus
Subscribe for More Information
August 7, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use